Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study
Adding pembrolizumab to enzalutamide did not improve efficacy outcomes for participants with chemotherapy-naive mCRPC. Additional toxicity was observed with the combination regimen.
Authors
- Jorge Salinas (ORCID: https://orcid.org/0000-0002-9193-820X)
- Jóse Ángel Arranz Arija (ORCID: https://orcid.org/0000-0003-0009-2147)
- Li Liang (ORCID: https://orcid.org/0000-0001-5918-2003)
- M. Retz
- Howard Gurney (ORCID: https://orcid.org/0000-0003-0217-5261)
- Lorea Villanueva (ORCID: https://orcid.org/0000-0003-1858-7076)
- Ray Manneh Kopp (ORCID: https://orcid.org/0000-0002-8106-9741)
- Cheol Kwak (ORCID: https://orcid.org/0000-0002-1987-2111)
- T. Todenhöfer
- Gero Kramer (ORCID: https://orcid.org/0000-0003-1982-6817)
- Mauricio Burotto (ORCID: https://orcid.org/0000-0002-7150-4033)
- Jeremy Graff
- N. Matsubara
- P.C. Fong
- Kazuo Imai (ORCID: https://orcid.org/0000-0002-8416-7371)
- B. Zurawski
- Arnulf Stenzl (ORCID: https://orcid.org/0000-0003-4207-9928)
- Jelena Todoric (ORCID: https://orcid.org/0000-0002-2669-3904)
- Raffaele Ratta (ORCID: https://orcid.org/0000-0002-2445-415X)
- David Pook (ORCID: https://orcid.org/0000-0002-1744-3022)
- Mariusz Kwiatkowski
- Kathryn Bylow
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of Auckland (NZ)
- Oregon Health & Science University (US)
- Medical College of Wisconsin (US)
- Fundación Chile (CL)
- Auckland City Hospital (NZ)
- TUM Klinikum (DE)
- Seoul National University Hospital (KR)
- Hospital General Universitario Gregorio Marañón (ES)
- Popular University of Cesar (CO)
- Klinik und Poliklinik für Urologie (DE)
- Centro de Excelencia en Procesos y Productos de Córdoba (AR)
- Monash Health (AU)
- Centrum Onkologii (PL)
- Fundación Arturo López Pérez (CL)
- Wojewódzki Szpital Zespolony (PL)
- National Cancer Center Hospital East (JP)
- Hôpital Foch (FR)
- Medical University of Vienna (AT)
- Macquarie University (AU)
Publication Details
- Journal
- Annals of Oncology
- Published
- 2025-05-16
- DOI
- https://doi.org/10.1016/j.annonc.2025.05.007
- Citations
- 11
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 16.70
Funders
- Merck Sharp and Dohme